The 6 analysts offering 12-month price forecasts for Zynerba Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 9.00 and a low estimate of 4.50. The median estimate represents a +46.79% increase from the last price of 5.45.
The current consensus among 7 polled investment analysts is to Buy stock in Zynerba Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.22
Reporting Date Aug 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.